Literature DB >> 10793497

Primary lymphoma of bone originating in a rib.

N Nishiyama1, S Nakatani, K Inoue, T Katoh, H Kinoshita.   

Abstract

Malignant lymphoma originating in the bone is rare and is now recognized as being an independent clinicopathologic entity known as primary lymphoma of bone. A 60-year-old man complaining of right chest and back pain consulted our hospital for further examination. Chest X-ray and computed tomogram revealed osteolysis and a surrounding soft tissue mass in the sixth right rib. An ultrasonically-guided needle biopsy of the tumor was performed, and histologic examination indicated the dense proliferation of similar-sized atypical cells with nucleoli and an irregular nuclear border. A diagnosis of diffuse, medium-sized non-Hodgkin's lymphoma, B-cell type was made. En block resection of the tumor and chest wall was performed. Macroscopically, the tumor measured 7.5 x 4.8 x 3.0 cm in diameter, and the histologic findings were similar to those of the preoperative needle biopsy. Unfortunately, postoperative treatment with radiation therapy and chemotherapy was ultimately unsuccessful, and a local recurrence and metastatic lesions appeared in the stomach and para-aortic abdominal lymph nodes 7 months after the first symptom appeared. The patient died 3 months later. Surgery was chosen as the initial therapy as it was considered that a rib resection would not result in serious respiratory compromise and the complete resection of the tumor would be superior to radiation therapy for local control. Some authors have reported that the surgical resection of a primary lymphoma of the bone originating in a rib can yield a good prognosis. However, it is a systemic disease and a more effective therapeutic strategy should be developed.

Entities:  

Mesh:

Year:  2000        PMID: 10793497     DOI: 10.1007/bf03218117

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  7 in total

1.  Primary reticulum cell sarcoma of bone. With emphasis on radiation therapy.

Authors:  C C Wang; D J Fleischli
Journal:  Cancer       Date:  1968-11       Impact factor: 6.860

2.  Therapy for primary non-Hodgkin's lymphoma of bone and a comparison of results with Ewing's sarcoma. Ten years' experience at the Istituto Ortopedico Rizzoli.

Authors:  G Bacci; N Jaffe; E Emiliani; J Van Horn; M Manfrini; P Picci; F Bertoni; F Gherlinzoni; M Campanacci
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

3.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

4.  Primary reticulum cell sarcoma of bone. Significance of clinical features upon the prognosis.

Authors:  H Shoji; T R Miller
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

5.  Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a Pediatric Oncology Group study.

Authors:  K Suryanarayan; J J Shuster; S S Donaldson; R E Hutchison; S B Murphy; M P Link
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

6.  Primary lymphoma of bone: relationship of radiographic appearance and prognosis.

Authors:  W C Phillips; S V Kattapuram; D E Doseretz; A K Raymond; A L Schiller; G Murphy; G Wyshak
Journal:  Radiology       Date:  1982-07       Impact factor: 11.105

7.  Primary lymphoma of bone: the relationship of morphologic diversity to clinical behavior.

Authors:  D E Dosoretz; A K Raymond; G F Murphy; K P Doppke; A L Schiller; C C Wang; H D Suit
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

  7 in total
  2 in total

1.  Chest Wall Mass as the Dominant Presentation of Low-Grade B-Cell Non-Hodgkin's Lymphoma: A Case Report.

Authors:  Sunita Nitin Sonavane; Sandip Basu
Journal:  World J Nucl Med       Date:  2022-07-19

2.  Cervical Radiculopathy as the Inaugural Manifestation of Non-Hodgkin's Lymphoma of Rib.

Authors:  Monika Puranik; Krati Khandelwal; Swapnil Puranik; Pragya Saxena; Prateek Bapat; Gaurav Khandelwal
Journal:  Ann Indian Acad Neurol       Date:  2021-04-21       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.